Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Taselisib Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Taselisib Rectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Taselisib Skin Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Taselisib Thyroid Gland Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Taselisib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Tcr Transduced T-Cells Neuroendocrine Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Telaglenastat Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Tiragolumab Colorectal Cancer	National Cancer Institute (NCI)	P2	CCC (51)
Tpst-1495 Colorectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Trastuzumab Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Trastuzumab Emtansine Colorectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Trastuzumab Emtansine Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Tuvusertib Castration-Resistant Prostate Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Ulixertinib Urinary Bladder Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Ulixertinib Colorectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Veliparib Myelofibrosis	National Cancer Institute (NCI)	P2	CCC (51)
Vismodegib Colorectal Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Vismodegib Glioma	National Cancer Institute (NCI)	P2	CCC (51)
Young Til Malignant Pancreatic Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Vorinostat Mixed Glioma	National Cancer Institute (NCI)	P1	CCC (51)
Abemaciclib Colorectal Cancer	National Cancer Institute (NCI)	P1/2	CCC (51)
Entinostat Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (51)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (51)
Pomalidomide Non-Hodgkin Lymphoma	National Cancer Institute (NCI)	P1/2	CCC (51)
Veliparib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (51)

Showing 2351 to 2375 of 3,272 assets

PreviousPage 95 of 131Next